Evidence map›Paper›PMID 42172631›Full record

ReviewHuman reproduction update2026

Sperm mitochondrial DNA copy number: a marker of male fertility and reproductive success.

Savni Sawant, Jeffrey M Mann, J Richard Pilsner

Abstract readReview
In one paragraph

Review in Human reproduction update, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Savni SawantDepartment of Biochemistry, Microbiology, Immunology, School of Medicine, Wayne State University, Detroit, MI, USA.
Jeffrey M MannC.S. Mott Center for Human Growth and Development, Department of Obstetrics and Gynecology, School of Medicine, Wayne State University, Detroit, MI, USA.
J Richard PilsnerC.S. Mott Center for Human Growth and Development, Department of Obstetrics and Gynecology, School of Medicine, Wayne State University, Detroit, MI, USA.ORCID 0000-0002-4541-6267

Funding

Sperm mitochondrial biomarkers and male reproductive healthR01HD110462 · NICHD · WAYNE STATE UNIVERSITY · PI J. Richard Pilsner, Brian William Whitcomb · 2024 to 2026
$2.0M
National Institute of Health (NIH) R01HD110462NICHD NIH HHS R01 HD110462NICHD NIH HHS R01HD110462
6 · The paper itself

Abstract

backgroundSperm mitochondrial DNA copy number (mtDNAcn) has emerged as a promising biomarker of sperm health, providing molecular insight beyond what is captured by standard semen analysis. Elevated sperm mtDNAcn has been consistently associated with lower sperm motility, concentration, and morphology, as well as prolonged time-to-pregnancy in natural conception and reduced fertilization potential in ART. OBJECTIVE AND RATIONALE: This review summarizes current evidence on the biological underpinnings of sperm mtDNAcn, including its regulation during spermatogenesis, the role of nuclear-encoded mitochondrial proteins such as TFAM (mitochondrial transcription factor A), and its potential epigenetic modulation through sperm DNA methylation. We evaluate general population and clinic-based studies linking sperm mtDNAcn to semen quality, couple fecundity, and early embryo development, while highlighting methodological considerations such as quantification techniques and somatic cell contamination. SEARCH

methodsA literature search was conducted to identify human studies evaluating sperm mtDNAcn in relation to male fertility, semen quality, reproductive outcomes, and embryology outcomes, as well as experimental models investigating the underlying biological mechanisms of mtDNA regulation during spermatogenesis via TFAM up to 1 April 2026. Searches were performed in PubMed, Web of Science, and Scopus using combinations of keywords and Medical Subject Headings (MeSH), including sperm mitochondrial DNA copy number, mtDNAcn, male infertility, pregnancy outcomes, ART outcomes, semen quality, sperm epigenetics, TFAM, mitochondrial transcription factor A, and sperm mtDNA regulation. Reference lists of relevant reviews and primary articles were manually screened to identify additional studies. Eligible studies included observational epidemiologic studies, clinical cohort studies, and experimental investigations that quantified sperm mtDNAcn and examined associations with semen parameters, fertility outcomes, or sperm epigenetics. No restrictions were placed on geographic location, while only articles published in English were considered. OUTCOMES: Across 21 epidemiologic, experimental, and clinical studies, elevated sperm mtDNAcn has been consistently associated with reduced sperm quality and inconsistently associated with diminished couple-level reproductive potential. Higher mtDNAcn is associated with lower sperm concentration, total sperm count, motility, and normal morphology, as well as higher sperm DNA fragmentation and chromatin abnormalities. It has also been linked to reduced likelihood of pregnancy and poorer embryo quality. Emerging evidence indicates associations between sperm mtDNAcn and altered nuclear DNA methylation patterns, supporting a role for mitochondrial-nuclear crosstalk. Collectively, these findings position sperm mtDNAcn as a biologically informative and clinically relevant indicator of male reproductive health that may complement, or potentially enhance, traditional semen analysis in both research and clinical settings. WIDER IMPLICATIONS: Sperm mtDNAcn holds promise as a biomarker for male fertility assessment, yet its full clinical potential has not been yet to be realized. Establishing standardized measurement protocols across sperm fractions and laboratory platforms will be essential for enabling cross-study comparability and facilitating clinical translation. Large prospective studies are needed to define clinically meaningful thresholds and better characterize the relationship between mtDNAcn alterations and spermatogenic impairment. Intervention strategies targeting mtDNA biogenesis and depletion, including antioxidant strategies and mitochondria-directed pharmacotherapy, warrant further investigation in the context of male fertility and fecundity. Collectively, sperm mtDNAcn may serve as an adjunctive marker in the assessment of male reproductive health and may inform future precision medicine approaches. REGISTRATION NUMBER: N/A.

Indexed as

DNA Copy Number VariationsDNA, MitochondrialFertilityInfertility, MaleSpermatozoaBiomarkersDNA MethylationEpigenesis, GeneticFemaleHumansMalePregnancySemen AnalysisSpermatogenesisSperm MotilityBiomarkersDNA, Mitochondrialmale infertilitymtDNA dysfunctionspermatogenesissperm mitochondrial DNA copy numberTFAM

Identifiers

PMID42172631
PMCPMC13538715

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.